{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T21:45:18Z","timestamp":1790459118214,"version":"4.1.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2017,6,26]],"date-time":"2017-06-26T00:00:00Z","timestamp":1498435200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1038\/aps.2017.38","type":"journal-article","created":{"date-parts":[[2017,6,26]],"date-time":"2017-06-26T09:01:01Z","timestamp":1498467661000},"page":"1257-1268","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["C33(S), a novel PDE9A inhibitor, protects against rat cardiac hypertrophy through upregulating cGMP signaling"],"prefix":"10.1038","volume":"38","author":[{"given":"Pan-xia","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo-ming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-dong","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-shuai","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-bin","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shao-rui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-qing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,26]]},"reference":[{"key":"BFaps201738_CR1","doi-asserted-by":"crossref","unstructured":"Liu R, Molkentin JD . Regulation of cardiac hypertrophy and remodeling through the dual-specificity MAPK phosphatases (DUSPs). J Mol Cell Cardiol 2016.","DOI":"10.1016\/j.yjmcc.2016.08.018"},{"key":"BFaps201738_CR2","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1016\/j.cellsig.2015.06.009","volume":"27","author":"S Cotecchia","year":"2015","unstructured":"Cotecchia S, Del Vescovo CD, Colella M, Caso S, Diviani D . The alpha1-adrenergic receptors in cardiac hypertrophy: signaling mechanisms and functional implications. Cell Signal 2015; 27: 1984\u201393.","journal-title":"Cell Signal"},{"key":"BFaps201738_CR3","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1291\/hypres.25.491","volume":"25","author":"H Takano","year":"2002","unstructured":"Takano H, Zou Y, Akazawa H, Toko H, Mizukami M, Hasegawa H, et al. Inhibitory molecules in signal transduction pathways of cardiac hypertrophy. Hypertens Res 2002; 25: 491\u20138.","journal-title":"Hypertens Res"},{"key":"BFaps201738_CR4","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1056\/NEJM199005313222203","volume":"322","author":"D Levy","year":"1990","unstructured":"Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP . Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322: 1561\u20136.","journal-title":"N Engl J Med"},{"key":"BFaps201738_CR5","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1152\/physrev.00030.2010","volume":"91","author":"SH Francis","year":"2011","unstructured":"Francis SH, Blount MA, Corbin JD . Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions. Physiol Rev 2011; 91: 651\u201390.","journal-title":"Physiol Rev"},{"key":"BFaps201738_CR6","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.yjmcc.2011.02.013","volume":"50","author":"J Inserte","year":"2011","unstructured":"Inserte J, Barba I, Poncelas-Nozal M, Hernando V, Agullo L, Ruiz-Meana M, et al. cGMP\/PKG pathway mediates myocardial postconditioning protection in rat hearts by delaying normalization of intracellular acidosis during reperfusion. J Mol Cell Cardiol 2011; 50: 903\u20139.","journal-title":"J Mol Cell Cardiol"},{"key":"BFaps201738_CR7","doi-asserted-by":"publisher","first-page":"e005975","DOI":"10.1161\/JAHA.112.005975","volume":"2","author":"J Inserte","year":"2013","unstructured":"Inserte J, Hernando V, Vilardosa U, Abad E, Poncelas-Nozal M, Garcia-Dorado D . Activation of cGMP\/protein kinase G pathway in postconditioned myocardium depends on reduced oxidative stress and preserved endothelial nitric oxide synthase coupling. J Am Heart Assoc 2013; 2: e005975.","journal-title":"J Am Heart Assoc"},{"key":"BFaps201738_CR8","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.1002\/stem.2118","volume":"33","author":"Y Wang","year":"2015","unstructured":"Wang Y, Li ZC, Zhang P, Poon E, Kong CW, Boheler KR, et al. Nitric oxide-cGMP-PKG pathway acts on Orai1 to inhibit the hypertrophy of human embryonic stem cell-derived cardiomyocytes. Stem Cells 2015; 33: 2973\u201384.","journal-title":"Stem Cells"},{"key":"BFaps201738_CR9","doi-asserted-by":"publisher","first-page":"11363","DOI":"10.1073\/pnas.162100799","volume":"99","author":"B Fiedler","year":"2002","unstructured":"Fiedler B, Lohmann SM, Smolenski A, Linnemuller S, Pieske B, Schroder F, et al. Inhibition of calcineurin-NFAT hypertrophy signaling by cGMP-dependent protein kinase type I in cardiac myocytes. Proc Natl Acad Sci U S A 2002; 99: 11363\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"BFaps201738_CR10","doi-asserted-by":"publisher","first-page":"47694","DOI":"10.1074\/jbc.M309661200","volume":"278","author":"A Zahabi","year":"2003","unstructured":"Zahabi A, Picard S, Fortin N, Reudelhuber TL, Deschepper CF . Expression of constitutively active guanylate cyclase in cardiomyocytes inhibits the hypertrophic effects of isoproterenol and aortic cons-triction on mouse hearts. J Biol Chem 2003; 278: 47694\u20139.","journal-title":"J Biol Chem"},{"key":"BFaps201738_CR11","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.pharmthera.2009.08.001","volume":"124","author":"RH Ritchie","year":"2009","unstructured":"Ritchie RH, Irvine JC, Rosenkranz AC, Patel R, Wendt IR, Horowitz JD, et al. Exploiting cGMP-based therapies for the prevention of left ventricular hypertrophy: NO* and beyond. Pharmacol Ther 2009; 124: 279\u2013300.","journal-title":"Pharmacol Ther"},{"key":"BFaps201738_CR12","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1016\/j.cellsig.2008.08.012","volume":"20","author":"M Zhang","year":"2008","unstructured":"Zhang M, Koitabashi N, Nagayama T, Rambaran R, Feng N, Takimoto E, et al. Expression, activity, and pro-hypertrophic effects of PDE5A in cardiac myocytes. Cell Signalling 2008; 20: 2231\u20136.","journal-title":"Cell Signalling"},{"key":"BFaps201738_CR13","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.pharmthera.2009.02.009","volume":"122","author":"EJ Tsai","year":"2009","unstructured":"Tsai EJ, Kass DA . Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics. Pharmacol Ther 2009; 122: 216\u201338.","journal-title":"Pharmacol Ther"},{"key":"BFaps201738_CR14","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1124\/pr.58.3.5","volume":"58","author":"AT Bender","year":"2006","unstructured":"Bender AT, Beavo JA . Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 2006; 58: 488\u2013520.","journal-title":"Pharmacol Rev"},{"key":"BFaps201738_CR15","doi-asserted-by":"publisher","first-page":"15559","DOI":"10.1074\/jbc.273.25.15559","volume":"273","author":"DA Fisher","year":"1998","unstructured":"Fisher DA, Smith JF, Pillar JS, St Denis SH, Cheng JB . Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase. J Biol Chem 1998; 273: 15559\u201364.","journal-title":"J Biol Chem"},{"key":"BFaps201738_CR16","doi-asserted-by":"publisher","first-page":"9045","DOI":"10.1021\/jm3007799","volume":"55","author":"PR Verhoest","year":"2012","unstructured":"Verhoest PR, Fonseca KR, Hou X, Proulx-Lafrance C, Corman M . Helal CJ, et al. Design and discovery of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (PF-04447943), a selective brain penetrant PDE9A inhibitor for the treatment of cognitive disorders. J Med Chem 2012; 55: 9045\u201354.","journal-title":"J Med Chem"},{"key":"BFaps201738_CR17","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1111\/j.1365-2141.2008.07264.x","volume":"142","author":"CB Almeida","year":"2008","unstructured":"Almeida CB, Traina F, Lanaro C, Canalli AA, Saad ST, Costa FF, et al. High expression of the cGMP-specific phosphodiesterase, PDE9A, in sickle cell disease (SCD) and the effects of its inhibition in erythroid cells and SCD neutrophils. Br J Haematol 2008; 142: 836\u201344.","journal-title":"Br J Haematol"},{"key":"BFaps201738_CR18","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.fertnstert.2012.05.015","volume":"98","author":"CB Hanna","year":"2012","unstructured":"Hanna CB, Yao S, Wu X, Jensen JT . Identification of phosphodiesterase 9A as a cyclic guanosine monophosphate-specific phosphodiesterase in germinal vesicle oocytes: a proposed role in the resumption of meiosis. Fertility Sterility 2012; 98: 487\u201395.e1.","journal-title":"Fertility Sterility"},{"key":"BFaps201738_CR19","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1038\/nutd.2011.9","volume":"1","author":"B Omar","year":"2011","unstructured":"Omar B, Banke E, Ekelund M, Frederiksen S, Degerman E . Alterations in cyclic nucleotide phosphodiesterase activities in omental and subcutaneous adipose tissues in human obesity. Nutr Diabetes 2011; 1: e13.","journal-title":"Nutr Diabetes"},{"key":"BFaps201738_CR20","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.bmcl.2009.03.024","volume":"19","author":"MP Deninno","year":"2009","unstructured":"Deninno MP, Andrews M, Bell AS, Chen Y, Eller-Zarbo C, Eshelby N, et al. The discovery of potent, selective, and orally bioavailable PDE9 inhibitors as potential hypoglycemic agents. Bioorg Med Chem Lett 2009; 19: 2537\u201341.","journal-title":"Bioorg Med Chem Lett"},{"key":"BFaps201738_CR21","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/nature14332","volume":"519","author":"DI Lee","year":"2015","unstructured":"Lee DI, Zhu G, Sasaki T, Cho GS, Hamdani N, Holewinski R, et al. Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease. Nature 2015; 519: 472\u20136.","journal-title":"Nature"},{"key":"BFaps201738_CR22","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1124\/mol.115.099747","volume":"88","author":"M Huang","year":"2015","unstructured":"Huang M, Shao Y, Hou J, Cui W, Liang B, Huang Y, et al. Structural asymmetry of phosphodiesterase-9A and a unique pocket for selective binding of a potent enantiomeric inhibitor. Mol Pharmacol 2015; 88: 836\u201345.","journal-title":"Mol Pharmacol"},{"key":"BFaps201738_CR23","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.abb.2014.08.007","volume":"562","author":"J Wang","year":"2014","unstructured":"Wang J, Liu Z, Feng X, Gao S, Xu S, Liu P . Tumor suppressor gene ING3 induces cardiomyocyte hypertrophy via inhibition of AMPK and activation of p38 MAPK signaling. Arch Biochem Biophys 2014; 562: 22\u201330.","journal-title":"Arch Biochem Biophys"},{"key":"BFaps201738_CR24","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/j.1476-5381.2012.01903.x","volume":"168","author":"SS Yu","year":"2013","unstructured":"Yu SS, Cai Y, Ye JT, Pi RB, Chen SR, Liu PQ, et al. Sirtuin 6 protects cardiomyocytes from hypertrophy in vitro via inhibition of NF-kappaB-dependent transcriptional activity. Br J Pharmacol 2013; 168: 117\u201328.","journal-title":"Br J Pharmacol"},{"key":"BFaps201738_CR25","doi-asserted-by":"publisher","first-page":"7899","DOI":"10.3892\/mmr.2015.4466","volume":"12","author":"P Li","year":"2015","unstructured":"Li P, Luo S, Pan C, Cheng X . Modulation of fatty acid metabolism is involved in the alleviation of isoproterenol-induced rat heart failure by fenofibrate. Mol Med Reports 2015; 12: 7899\u2013906.","journal-title":"Mol Med Reports"},{"key":"BFaps201738_CR26","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.mce.2014.05.010","volume":"392","author":"M Liu","year":"2014","unstructured":"Liu M, Li Z, Chen GW, Li ZM, Wang LP, Ye JT, et al. AG-690\/11026014, a novel PARP-1 inhibitor, protects cardiomyocytes from Ang II-induced hypertrophy. Mol Cell Endocrinol 2014; 392: 14\u201322.","journal-title":"Mol Cell Endocrinol"},{"key":"BFaps201738_CR27","doi-asserted-by":"publisher","first-page":"2852","DOI":"10.1111\/bph.13091","volume":"172","author":"XJ Feng","year":"2015","unstructured":"Feng XJ, Gao H, Gao S, Li Z, Li H, Lu J, et al. The orphan receptor NOR1 participates in isoprenaline-induced cardiac hypertrophy by regulating PARP-1. Br J Pharmacol 2015; 172: 2852\u201363.","journal-title":"Br J Pharmacol"},{"key":"BFaps201738_CR28","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1161\/CIRCRESAHA.116.306082","volume":"116","author":"RK Perera","year":"2015","unstructured":"Perera RK, Sprenger JU, Steinbrecher JH, Hubscher D, Lehnart SE, Abesser M, et al. Microdomain switch of cGMP-regulated phosphodiesterases leads to ANP-induced augmentation of beta-adrenoceptor-stimulated contractility in early cardiac hypertrophy. Circ Res 2015; 116: 1304\u201311.","journal-title":"Circ Res"},{"key":"BFaps201738_CR29","doi-asserted-by":"publisher","first-page":"12925","DOI":"10.1073\/pnas.1414364111","volume":"111","author":"E Patrucco","year":"2014","unstructured":"Patrucco E, Domes K, Sbroggio M, Blaich A, Schlossmann J, Desch M, et al. Roles of cGMP-dependent protein kinase I (cGKI) and PDE5 in the regulation of Ang II-induced cardiac hypertrophy and fibrosis. Proc Natl Acad Sci U S A 2014; 111: 12925\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"BFaps201738_CR30","doi-asserted-by":"publisher","first-page":"e14227","DOI":"10.1371\/journal.pone.0014227","volume":"5","author":"W Mokni","year":"2010","unstructured":"Mokni W, Keravis T, Etienne-Selloum N, Walter A, Kane MO . Schini-Kerth VB, et al. Concerted regulation of cGMP and cAMP phosphodiesterases in early cardiac hypertrophy induced by angiotensin II. PLoS One 2010; 5: e14227.","journal-title":"PLoS One"},{"key":"BFaps201738_CR31","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1093\/eurheartj\/ehr445","volume":"34","author":"S Frantz","year":"2013","unstructured":"Frantz S, Klaiber M, Baba HA, Oberwinkler H, Volker K, Gabetaner B, et al. Stress-dependent dilated cardiomyopathy in mice with cardiomyocyte-restricted inactivation of cyclic GMP-dependent protein kinase I. Eur Heart J 2013; 34: 1233\u201344.","journal-title":"Eur Heart J"},{"key":"BFaps201738_CR32","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s00395-010-0097-0","volume":"105","author":"A Gorbe","year":"2010","unstructured":"Gorbe A, Giricz Z, Szunyog A, Csont T, Burley DS, Baxter GF, et al. Role of cGMP-PKG signaling in the protection of neonatal rat cardiac myocytes subjected to simulated ischemia\/reoxygenation. Basic Res Cardiol 2010; 105: 643\u201350.","journal-title":"Basic Res Cardiol"},{"key":"BFaps201738_CR33","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.yjmcc.2010.09.010","volume":"49","author":"JR Pena","year":"2010","unstructured":"Pena JR, Szkudlarek AC, Warren CM, Heinrich LS, Gaffin RD, Jagatheesan G, et al. Neonatal gene transfer of SERCA2a delays onset of hypertrophic remodeling and improves function in familial hypertrophic cardiomyopathy. J Mol Cell Cardiol 2010; 49: 993\u20131002.","journal-title":"J Mol Cell Cardiol"},{"key":"BFaps201738_CR34","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1161\/01.CIR.102.18.2249","volume":"102","author":"N Satoh","year":"2000","unstructured":"Satoh N, Suter TM, Liao R, Colucci WS . Chronic alpha-adrenergic receptor stimulation modulates the contractile phenotype of cardiac myocytes in vitro. Circulation 2000; 102: 2249\u201354.","journal-title":"Circulation"},{"key":"BFaps201738_CR35","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1161\/CIRCULATIONAHA.115.020086","volume":"134","author":"AS Helms","year":"2016","unstructured":"Helms AS, Alvarado FJ, Yob J, Tang VT, Pagani F, Russell MW, et al. Genotype-dependent and -independent calcium signaling dysregulation in human hypertrophic cardiomyopathy. Circulation 2016; 134: 1738\u201348.","journal-title":"Circulation"},{"key":"BFaps201738_CR36","doi-asserted-by":"crossref","first-page":"39207","DOI":"10.18632\/oncotarget.9393","volume":"7","author":"J Dong","year":"2016","unstructured":"Dong J, Gao C, Liu J, Cao Y, Tian L . TSH inhibits SERCA2a and the PKA\/PLN pathway in rat cardiomyocytes. Oncotarget 2016; 7: 39207\u201315.","journal-title":"Oncotarget"},{"key":"BFaps201738_CR37","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1249\/MSS.0000000000000921","volume":"48","author":"JH Kim","year":"2016","unstructured":"Kim JH, Trilk JL, Smith R, Asif I, Maddux PT, Ko YA, et al. Cardiac structure and function in elite para-cyclists with spinal cord injury. Med Sci Sports Exerc 2016; 48: 1431\u20137.","journal-title":"Med Sci Sports Exerc"},{"key":"BFaps201738_CR38","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1001\/jama.2013.2024","volume":"309","author":"MM Redfield","year":"2013","unstructured":"Redfield MM, Chen HH, Borlaug BA, Semigran MJ, Lee KL, Lewis G, et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 2013; 309: 1268\u201377.","journal-title":"JAMA"},{"key":"BFaps201738_CR39","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/hr.2015.133","volume":"39","author":"H Watanabe","year":"2016","unstructured":"Watanabe H, Iwanaga Y, Miyaji Y, Yamamoto H, Miyazaki S . Renal denervation mitigates cardiac remodeling and renal damage in Dahl rats: a comparison with beta-receptor blockade. Hypertens Res 2016; 39: 217\u201326.","journal-title":"Hypertens Res"},{"key":"BFaps201738_CR40","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.cca.2014.10.031","volume":"443","author":"M Emdin","year":"2015","unstructured":"Emdin M, Fatini C, Mirizzi G, Poletti R, Borrelli C, Prontera C, et al. Biomarkers of activation of renin-angiotensin-aldosterone system in heart failure: how useful, how feasible? Clin Chim Acta 2015; 443: 85\u201393.","journal-title":"Clin Chim Acta"},{"key":"BFaps201738_CR41","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1111\/j.1440-1681.2004.04063.x","volume":"31","author":"Y Zhang","year":"2004","unstructured":"Zhang Y, Yan J, Chen K, Song Y, Lu Z, Chen M, et al. Different roles of alpha1-adrenoceptor subtypes in mediating cardiomyocyte protein synthesis in neonatal rats. Clin Exp Pharmacol Physiol 2004; 31: 626\u201333.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"BFaps201738_CR42","doi-asserted-by":"publisher","first-page":"e1006038","DOI":"10.1371\/journal.pgen.1006038","volume":"12","author":"JJ Wang","year":"2016","unstructured":"Wang JJ, Rau C, Avetisyan R, Ren S, Romay MC, Stolin G . Genetic dissection of cardiac remodeling in an isoproterenol-induced heart failure mouse model. PLoS Genet 2016; 12: e1006038.","journal-title":"PLoS Genet"},{"key":"BFaps201738_CR43","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.ijcard.2017.01.071","volume":"236","author":"X Zhang","year":"2017","unstructured":"Zhang X, Cheng HJ, Zhou P, Kitzman DW, Ferrario CM, Li WM, et al. Cellular basis of angiotensin-(1-7)-induced augmentation of left ventricular functional performance in heart failure. Int J Cardiol 2017; 236: 405\u201312.","journal-title":"Int J Cardiol"},{"key":"BFaps201738_CR44","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/1440-1681.12176","volume":"41","author":"H Li","year":"2014","unstructured":"Li H, Lu ZZ, Chen C, Song Y, Xiao H, Zhang YY . Echocardiographic assessment of beta-adrenoceptor stimulation-induced heart failure with reduced heart rate in mice. Clin Exp Pharmacol Physiol 2014; 41: 58\u201366.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"BFaps201738_CR45","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1161\/01.HYP.0000056601.29613.DD","volume":"41","author":"D Badenhorst","year":"2003","unstructured":"Badenhorst D, Veliotes D, Maseko M, Tsotetsi OJ, Brooksbank R, Naidoo A, et al. Beta-adrenergic activation initiates chamber dilatation in concentric hypertrophy. Hypertension 2003; 41: 499\u2013504.","journal-title":"Hypertension"},{"key":"BFaps201738_CR46","doi-asserted-by":"publisher","first-page":"401","DOI":"10.3109\/10641963.2012.739235","volume":"35","author":"S Perlini","year":"2013","unstructured":"Perlini S, Chung ES, Aurigemma GP, Meyer TE . Alterations in early filling dynamics predict the progression of compensated pressure overload hypertrophy to heart failure better than abnormalities in midwall systolic shortening. Clin Exp Hypertens 2013; 35: 401\u201311.","journal-title":"Clin Exp Hypertens"},{"key":"BFaps201738_CR47","doi-asserted-by":"publisher","first-page":"585","DOI":"10.2174\/092986707780059715","volume":"14","author":"MC Cerra","year":"2007","unstructured":"Cerra MC, Pellegrino D . Cardiovascular cGMP-generating systems in physiological and pathological conditions. Curr Med Chem 2007; 14: 585\u201399.","journal-title":"Curr Med Chem"},{"key":"BFaps201738_CR48","doi-asserted-by":"publisher","first-page":"16604","DOI":"10.1073\/pnas.1415933111","volume":"111","author":"IY Kuo","year":"2014","unstructured":"Kuo IY, Kwaczala AT, Nguyen L, Russell KS, Campbell SG, Ehrlich BE . Decreased polycystin 2 expression alters calcium-contraction coupling and changes beta-adrenergic signaling pathways. Proc Natl Acad Sci U S A 2014; 111: 16604\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"BFaps201738_CR49","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1093\/cvr\/cvu163","volume":"103","author":"J Inserte","year":"2014","unstructured":"Inserte J, Hernando V, Ruiz-Meana M, Poncelas-Nozal M, Fernandez C, Agullo L, et al. Delayed phospholamban phosphorylation in post-conditioned heart favours Ca2+ normalization and contributes to protection. Cardiovasc Res 2014; 103: 542\u201353.","journal-title":"Cardiovasc Res"},{"key":"BFaps201738_CR50","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1161\/01.RES.85.9.848","volume":"85","author":"B Huang","year":"1999","unstructured":"Huang B, Wang S, Qin D, Boutjdir M, El-Sherif N . Diminished basal phosphorylation level of phospholamban in the postinfarction remodeled rat ventricle: role of beta-adrenergic pathway, G(i) protein, phosphodiesterase, and phosphatases. Circ Res 1999; 85: 848\u201355.","journal-title":"Circ Res"},{"key":"BFaps201738_CR51","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.jss.2012.04.066","volume":"178","author":"MR Moon","year":"2012","unstructured":"Moon MR, Aziz A, Lee AM, Moon CJ, Okada S, Kanter EM, et al. Differential calcium handling in two canine models of right ventricular pressure overload. J Surg Res 2012; 178: 554\u201362.","journal-title":"J Surg Res"},{"key":"BFaps201738_CR52","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/S0008-6363(01)00489-8","volume":"53","author":"JB Sande","year":"2002","unstructured":"Sande JB, Sjaastad I, Hoen IB, Bokenes J, Tonnessen T, Holt E, et al. Reduced level of serine(16) phosphorylated phospholamban in the failing rat myocardium: a major contributor to reduced SERCA2 activity. Cardiovasc Res 2002; 53: 382\u201391.","journal-title":"Cardiovasc Res"},{"key":"BFaps201738_CR53","doi-asserted-by":"publisher","first-page":"H1719","DOI":"10.1152\/ajpheart.00937.2009","volume":"298","author":"MY Jeong","year":"2010","unstructured":"Jeong MY, Walker JS, Brown RD, Moore RL, Vinson CS, Colucci WS, et al. AFos inhibits phenylephrine-mediated contractile dysfunction by altering phospholamban phosphorylation. Am J Physiol Heart Circ Physiol 2010; 298: H1719\u201326.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"BFaps201738_CR54","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/j.1749-6632.1998.tb08258.x","volume":"853","author":"J Colyer","year":"1998","unstructured":"Colyer J . Phosphorylation states of phospholamban. Ann N Y Acad Sci 1998; 853: 79\u201391.","journal-title":"Ann N Y Acad Sci"},{"key":"BFaps201738_CR55","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1002\/iub.545","volume":"63","author":"A Zarain-Herzberg","year":"2011","unstructured":"Zarain-Herzberg A, Fragoso-Medina J, Estrada-Aviles R . Calcium-regulated transcriptional pathways in the normal and pathologic heart. IUBMB life 2011; 63: 847\u201355.","journal-title":"IUBMB life"},{"key":"BFaps201738_CR56","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1139\/y2012-057","volume":"90","author":"A Zarain-Herzberg","year":"2012","unstructured":"Zarain-Herzberg A, Estrada-Aviles R, Fragoso-Medina J . Regulation of sarco(endo)plasmic reticulum Ca2+-ATPase and calsequestrin gene expression in the heart. Can J Physiol Pharmacol 2012; 90: 1017\u201328.","journal-title":"Can J Physiol Pharmacol"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/aps201738.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/aps201738","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/aps.2017.38","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/aps201738.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:36:43Z","timestamp":1684413403000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/aps201738"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,26]]},"references-count":56,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["BFaps201738"],"URL":"https:\/\/doi.org\/10.1038\/aps.2017.38","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,26]]},"assertion":[{"value":"30 November 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}